- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04031664
A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)
A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome):a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Yanming Xie, BA
- Phone Number: 86-13911112416
- Email: ktzu2018@163.com
Study Contact Backup
- Name: Kun Ma, Doctor
- Phone Number: 86-13521781839
- Email: wlxing@126.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- (1) Women aged 20-50;
- (2) Sexual History ;
- (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the following specifications are as follows: A. uterine tenderness, or adnexal tenderness, or cervical lifting pain; B. axillary body temperature < 38 C. blood routine white blood cell count < 1.1 times the upper limit of normal value; D. blood routine neutrophil percentage < 90%; All of the above four items are available. Exclusion Criteria:
- (4)4<McCormack<12;
- (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome, A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C. fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the above four items are all available;
- (6)Those who agree to participate in this clinical trial and sign the informed consent form.
Exclusion Criteria:
- (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;
- (2) To identify the pathogen as Neisseria gonorrhoeae;
- (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis, vulvovaginal candidiasis, bacterial vaginosis, etc.;
- (4)Those with critical condition or surgical indications, such as fallopian tube and ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;
- (5)In patients with severe primary diseases such as heart, brain and hematopoietic system, ALT of liver function is higher than the upper limit of normal value, and Cr of renal function is higher than the upper limit of normal value;
- (6)One month before admission, Chinese and Western medicines were used to treat the disease, which made it difficult to judge the efficacy of drugs;
- (7)Anaphylactic constitution or persons known to be allergic to the medicines and their components used in this test ;
- (8)Researchers do not consider it appropriate to participate in this clinical trial;
- (9)Suspected or true history of alcohol and drug abuse, or other pathological changes or conditions that reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the working environment, unstable living environment, etc., are liable to lead to lost interviews, according to the judgement of researchers;
- (10)Participation in other clinical researchers within 3 months before admission;
- (11)Patients with suspected or confirmed quinolone contraindications, central or peripheral neuropathy, epilepsy, and depression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Qianjin Capsule of Gynaecology
On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days. One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc. |
To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
|
Placebo Comparator: Antibiotics alone group
Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days. One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc. |
To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The MCCormack scale scores of 184 subjects will be assessed
Time Frame: Change from base line on the 56 days after discontinuation
|
assessment of the 70% reduction rate after treatment
|
Change from base line on the 56 days after discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The neutrophils of 184 participants will be assessed
Time Frame: Change from base line on the 28 days of medication and 56 days after discontinuation
|
assessment of neutrophils returning to normal reference range
|
Change from base line on the 28 days of medication and 56 days after discontinuation
|
The whole blood reduced viscosity from hemorheological tests of 184 participants will be assessed
Time Frame: Change from base line on the 28 day of medication.
|
assessment of whole blood viscosity returning to normal reference range
|
Change from base line on the 28 day of medication.
|
The plasma viscosity from hemorheological tests of 184 participants will be assessed
Time Frame: Change from base line on the 28 day of medication.
|
assessment of the plasma viscosity returning to normal reference range
|
Change from base line on the 28 day of medication.
|
The fibrinogen determination from hemorheological tests of 184 participants will be assessed
Time Frame: Change from base line on the 28 day of medication.
|
assessment of the fibrinogen determination returning to normal reference range
|
Change from base line on the 28 day of medication.
|
The CRP of 184 participants will be assessed
Time Frame: Change from base line on the 28 day of medication.
|
assessment of the CRP returning to normal reference range
|
Change from base line on the 28 day of medication.
|
The volume of liquid on B-mode of 184 subjects will be assessed
Time Frame: After 28 days of medication
|
The changes of the volume of liquid on B-mode at different observation points before and after treatment will be assessed
|
After 28 days of medication
|
The white blood cells of 184 participants will be assessed
Time Frame: Change from base line on the 28 days of medication and 56 days after discontinuation
|
assessment of the white blood returning to normal reference range
|
Change from base line on the 28 days of medication and 56 days after discontinuation
|
The TCM syndrome scores of 184 subjects will be assessed
Time Frame: Change from base line on the 56 days after discontinuation
|
assessment of the 70% reduction rate after treatment
|
Change from base line on the 56 days after discontinuation
|
The VAS score of 184 subjects will be assessed
Time Frame: Change from base line on the 56 days after discontinuation
|
assessment of the 70% reduction rate after treatment
|
Change from base line on the 56 days after discontinuation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
Observe the incidence of adverse events after medication
|
Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
Change of liver function
Time Frame: Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
To observe whether ALT and AST are within the normal reference range after medication.
|
Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
Change of renal function
Time Frame: Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
To observe whether creatinine and urea nitrogen are within the normal reference range after treatment.
|
Change from base line on the 21 day of medication and from 28 days on 56 days after the end of
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yanming Xie, BA, Institute of Basic Research in Clinical Medicine, China Academy of Chinese
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Qianjin Capsule
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Inflammatory Diseases
-
Kangbuk Samsung HospitalRecruiting
-
China Academy of Chinese Medical SciencesPeking University First Hospital; Peking Union Medical College Hospital; Chengdu... and other collaboratorsUnknown
-
Johns Hopkins UniversityNational Institute of Nursing Research (NINR)CompletedPelvic Inflammatory Disease (PID)United States
-
Aijun SunSecond Hospital of Jilin University; Guangzhou Women and Children's Medical... and other collaboratorsUnknownChronic Pelvic PainChina
-
Beijing Konruns Pharmaceutical Co., Ltd.CompletedChronic Pelvic PainChina
-
RAPbarcelonaCompletedChronic Pain | Pelvic Pain | Physical Therapy | Chronic Pain Syndrome | Pelvic Pain Syndrome | Chronic Pelvic Inflammatory DiseaseSpain
-
Children's Hospital of PhiladelphiaCompletedPelvic Inflammatory DiseaseUnited States
-
University of KarachiZhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China; Center for bioequivalence...CompletedPelvic Inflammatory DiseasePakistan
-
Shanghai University of Traditional Chinese MedicineUnknown
-
BayerCompletedPelvic Inflammatory DiseaseGermany, Italy, France, Hungary, Sweden, Poland, South Africa, Russian Federation, Finland, Denmark, Lithuania, United Kingdom, Greece
Clinical Trials on Qianjin Capsule of Gynaecology
-
Aijun SunSecond Hospital of Jilin University; Guangzhou Women and Children's Medical... and other collaboratorsUnknownChronic Pelvic PainChina
-
Imperial College LondonImperial College Healthcare NHS TrustRecruiting
-
Shanghai Zhongshan HospitalShanghai Wu Mengchao Medical Foundation; Shanghai Ankang Pharmaceutical Co....Completed
-
Guang'anmen Hospital of China Academy of Chinese...UnknownKnee OsteoarthritisChina
-
Shineway Pharmaceutical Co.,LtdActive, not recruiting
-
Kwang-Ha YooHanlim Pharm. Co., Ltd.CompletedAcute BronchitisKorea, Republic of
-
Guang'anmen Hospital of China Academy of Chinese...UnknownKnee OsteoarthritisChina
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux DiseaseUnited States
-
Centre Hospitalier Universitaire DijonUnknownTrabulectomy | Deep SclerectomyFrance
-
Galera Therapeutics, Inc.Completed